title: Pharmacokinetic study of levetiracetam in children.
abstract: OBJECTIVE
  The pharmacokinetics of the novel antiepileptic drug (AED) levetiracetam and its major metabolite, ucb L057, were studied in children with partial seizures in a multicenter, open-label, single-dose study.
  
  
  METHODS
  Twenty-four children (15 boys, nine girls), 6 to 12 years old, received a single dose of levetiracetam (20 mg/kg) as an adjunct to their stable regimen of a single concomitant AED, followed by a 24-h pharmacokinetic evaluation.
  
  
  RESULTS
  In children, the half-lives of levetiracetam and its metabolite ucb L057 were 6.0 +/- 1.1 and 8.1 +/-2.7 hours, respectively. The Cmax and area under the curve (AUC) of levetiracetam equated for a 1-mg/kg dose were lower in children (Cmax, norm=1.33 plus minus 0.35 microg/ml; AUCnorm=12.4 +/- 3.5 microg/h/ml) than in adults (Cmax, norm=1.38 +/- 0.05 microg/ml; AUCnorm=11.48 +/- 0.63 microg/h/ml), whereas the renal clearance was higher. The apparent body clearance (1.43 +/- 0.36 ml/min/kg) was approximately 30-40% higher in children than in adults. Levetiracetam was generally well tolerated.
  
  
  CONCLUSIONS
  On the basis of these data, a daily maintenance dose equivalent to 130-140% of the usual daily adult maintenance dosage (1,000-3,000 mg/day) in two divided doses, on a weight-normalized level (mg/kg/day) is initially recommended. Clinical efficacy trials in children are ongoing with dosages of 20 to 60 mg/kg/day.
authors.affiliation: Division of Child Neurology, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia 23298-0211, USA. jpellock@gems.vcu.edu
authors.forename: J M
authors.initials: JM
authors.lastname: Pellock
authors.forename: T A
authors.initials: TA
authors.lastname: Glauser
authors.forename: E M
authors.initials: EM
authors.lastname: Bebin
authors.forename: N B
authors.initials: NB
authors.lastname: Fountain
authors.forename: F J
authors.initials: FJ
authors.lastname: Ritter
authors.forename: R M
authors.initials: RM
authors.lastname: Coupez
authors.forename: W D
authors.initials: WD
authors.lastname: Shields
mesh_terms: D000328:Adult; D000367:Age Factors; D000927:Anticonvulsants / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002648:Child; D003401:Creatine / Q000378:metabolism; D004827:Epilepsy / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D000077287:Levetiracetam; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D010889:Piracetam / Q000031:analogs & derivatives* / Q000493:pharmacokinetics* / Q000627:therapeutic use
chemical_list: D000927:Anticonvulsants; D000077287:Levetiracetam; D003401:Creatine; D010889:Piracetam